UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
—————————
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
—————————
For the month of January 2005
Commission File Number: 001-31368
SANOFI-AVENTIS
(Translation of registrant’s name into English)
174, avenue de France, 75013 Paris, FRANCE
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
|
Form 20-F [ X ] |
Form 40-F [ |
] |
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): _____
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): _____
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
|
Yes [ |
] |
No [ X ] |
If “Yes” marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-________
On January 17, 2005, sanofi-aventis issued the press release attached hereto as Exhibit 99.1 which is incorporated herein by reference.
Exhibit List
|
Exhibit No. |
Description |
|
Exhibit 99.1 |
Press Release, dated January 17, 2005, announcing US FDA approval of Menactra™ Vaccine. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Dated: January 18, 2005 |
|
| SANOFI-AVENTIS By: /s/ Jean-Claude Leroy Name: Jean-Claude Leroy Title: Senior Vice President & Chief Financial Officer |
Exhibit Index
|
Exhibit No. |
Description |
|
Exhibit 99.1 |
Press Release, dated January 17, 2005, announcing US FDA approval of Menactra™ Vaccine. |